Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

Market Cap	34.20B
Revenue (ttm)	25.56B
Net Income (ttm)	1.96B
Shares Out	1.61B
EPS (ttm)	1.19
PE Ratio	17.85
Forward PE	14.67
Dividend	0.30 (1.41%)
Ex-Dividend Date	Oct 11, 2024

Volume	27,600,680
Average Volume	18,514,579
Open	21.20
Previous Close	21.21
Day's Range	21.02 - 21.52
52-Week Range	15.68 - 25.90
Beta	0.84
RSI	60.37
Earnings Date	Apr 29, 2025

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection for endotracheal intubation, and general anesthesia using artificial respiration; remifentanil hydrochloride for Injection for induction and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients requiring opioid analgesia; nabuphine hydrochloride injection for induction of anesthesia; alfentanil hydrochloride injectio...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 17,676
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600079

Financial Performance

In 2023, SHA:600079's revenue was 24.52 billion, an increase of 9.79% compared to the previous year's 22.34 billion. Earnings were 2.13 billion, a decrease of -14.07%.